DePuy Synthes Spine, Biomaterials Granted Exclusive Right to Market Cellular Allograft Product

DePuy Synthes Spine and DePuy Synthes Biomaterials have gained the exclusive worldwide rights to market LifeNet Health’s cellular allograft product.

Advertisement

This agreement is DePuy Synthes Spine’s first move into cellular allografts for spinal fusion.

LifeNet Health is a developer of allograft bioimplants and cellular therapies.

More Articles on Devices:
Texas Hospital Purchases Second Renaissance Spine System From Mazor Robotics
Smith & Nephew to Purchase ArthroCare for $1.7B
Global Medical Device Market to Reach $434.4B by 2017

Advertisement

Next Up in Spinal Tech

  • Zavation Medical has acquired ChoiceSpine, and Derek Kuyper will be CEO of the combined company, according to a Feb. 26…

Advertisement

Comments are closed.